The American College of Cardiology (ACC) and the American Heart Association (AHA) have released updated clinical guidelines on the management of dyslipidemia, recommending that cholesterol screening begin at 19 years of age. The 2026 guideline aims to detect abnormal cholesterol levels earlier and reduce long-term cardiovascular risk.1
The recommendations were developed by cardiovascular experts from multiple professional societies and published as part of an updated framework for preventing atherosclerotic cardiovascular disease (ASCVD). Health authorities emphasize that identifying lipid abnormalities early can help prevent heart disease later in life.
According to the guideline, individuals should undergo their first cholesterol test at 19 years of age. If no major risk factors are present, lipid levels should be reassessed periodically, often every five years.
The guideline also recommends more detailed cardiovascular risk assessment tools that estimate a person’s lifetime risk of heart disease rather than focusing only on short-term outcomes.
These measures allow physicians to identify risk earlier and guide preventive interventions such as lifestyle modification or medication.
As reported in The Newsroom, Dr. Roger Blumenthal, MD, FACC, FAHA, chair of the guideline writing committee, said
We know 80% or more of cardiovascular disease is preventable and elevated LDL cholesterol, sometimes referred to as ‘bad’ cholesterol, is a major part of that risk. While we want to try to optimize healthy lifestyle habits as the first step to lower cholesterol, we realize that if lipid numbers aren’t within the desirable range after a period of lifestyle optimization, we should consider adding lipid-lowering medication earlier than we would have considered 10 years ago. And lower LDL cholesterol for longer, just like lower blood pressure for longer, results in much greater protection against future heart attack and stroke risk.
Dr. Roger Blumenthal, Director of the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease
Cholesterol accumulation in the arteries develops gradually over many years. Elevated levels of low-density lipoprotein cholesterol (LDL-C) can lead to plaque formation in blood vessels, increasing the risk of heart attack and stroke.
Because this process often begins in early adulthood, health organizations now emphasize the importance of detecting abnormal cholesterol levels before symptoms appear.
Early screening may help clinicians identify individuals with genetic lipid disorders or other risk factors that can accelerate cardiovascular disease. The guideline also highlights that certain populations, including people of South Asian origin, may face a higher risk of heart disease and therefore benefit from earlier monitoring.
These tools incorporate factors such as cholesterol levels, blood pressure, smoking status, metabolic conditions, and family history. By evaluating multiple variables, clinicians can identify individuals who may benefit from early intervention even if their short-term risk appears low.
The guideline also encourages physicians to begin evaluating long-term cardiovascular risk as early as 30 years of age, allowing preventive strategies to start sooner.
With this new assessment tool, we can better estimate cardiovascular risk using health information already obtained during an annual physical—cholesterol, blood pressure readings and other personal information such as age and health habits—and then further personalize the risk score for each individual by looking at ‘risk enhancers,’ which can help guide the need for lipid-lowering therapy.
Dr. Roger Blumenthal, Director of the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease
The guideline also updates recommended LDL cholesterol targets for different risk groups.
For individuals with moderate cardiovascular risk, clinicians are advised to aim for LDL levels below 100 mg/dL. For those at higher risk, the recommended target is below 70 mg/dL.
Lifestyle measures remain the first step in cholesterol management. These include dietary changes, regular physical activity, weight management, and smoking cessation.
If lifestyle modifications do not sufficiently reduce LDL levels, physicians may prescribe statins, which decrease cholesterol production in the liver. Additional lipid-lowering medications may be considered when statins alone do not achieve target levels.1
Having healthy LDL-cholesterol levels or high-density lipoprotein-cholesterol (HDL-C), traditionally thought of as ‘good’ cholesterol, isn’t necessarily a ‘get out of jail free’ card. Measuring other biomarkers can give a more complete picture of someone’s cardiovascular risk and help inform decisions about whether lipid-lowering therapy is needed sooner rather than later or if more intensive therapy is warranted.
Dr. Roger Blumenthal, Director of the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease
Cardiovascular disease continues to be a major cause of illness and death worldwide. The 2026 dyslipidemia guidelines emphasize prevention throughout adulthood rather than starting treatment only after risk increases in middle age.
By recommending cholesterol testing beginning at age 19, along with improved risk assessment and treatment strategies, the updated guidance aims to detect cardiovascular risk earlier and support long-term heart health.
1. Blumenthal, R., P. Morris, M. Gaudino, et al. 2026. “2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.” Journal of the American College of Cardiology. https://doi.org/10.1016/j.jacc.2025.11.016.
(Rh/SS/MSM)
